Welcome to Xeraya Capital
At Xeraya, all of our activities, expertise, and resources focus solely on the Life Sciences sector. We look to generate superior investment returns by cultivating value over the long-term. We collaborate with and nurture our portfolio companies. We ensure that every investment we make not only delivers financial returns but brings benefits to humanity, including Malaysia and our surrounding region.
Medical Technologies
Bringing medical innovation to all.
View More
Healthcare Biotech
Reshaping medical standard of care.
View More
Bio Renewables & Bio Industrial
Creating a cleaner world for the future.
View More
Portfolio Highlights
P2 Science
P2 Science is a venture-backed, renewable chemicals company, co-founded by Yale scientists and has developed a unique, bio-refining process for converting biomass—including vegetable oils—into high-value, specialty chemicals including flavour and fragrance ingredients.
Read more
Chrono Therapeutics
Chrono Therapeutics, Inc., based in Hayward, California, is developing a novel smoking cessation therapy - the first wearable transdermal drug delivery device that optimises drug dosing through digitalised timed delivery. Chrono’s solution revolutionises how people quit the addiction through medication timed to their cravings and with the addition of proactive, real-time coaching just when help is needed the most.
Read more
Mitralign is a venture-backed, valve repair company located near Boston, Massachusetts, U.S.A. that is developing an innovative therapy to address life-threatening cardiac valve conditions affecting more than 5 million patients in the U.S.A. alone.
Read more
Iconic Therapeutics
Iconic Therapeutics, based in San Francisco, California, is a clinical stage biopharmaceutical company dedicated to translating an understanding of the role of Tissue Factor biology to new therapeutics for retinal disease and cancer.
Read more
OptiScan Biomedical Corporation
OptiScan Biomedical Corporation (“OptiScan”) is based in Hayward, California. It has developed an innovative continuous monitoring platform for use in hospital intensive care units (“ICU”) to support clinicians in detecting changes more rapidly in critically ill patients, enabling more timely intervention.
Read more
Acutus Medical
Acutus Medical, based in San Diego, U.S.A. is a global heart rhythm technology company that has developed the AcQMap system that maps Atrial Fibrillation (“AF”) and other complex arrhythmias. The system identifies the mechanism of those arrhythmias and provides a guide for ablation therapy. Acutus has pioneered a new and novel approach using minimally invasive Dipole Density technology, generating high resolution, real-time, 3D images of the heart, providing treatment options for over 10 million people afflicted with AF globally.
Read more
Vittamed is a neurodiagnostics medical device company with offices in Kaunas, Lithuania and Boston, USA. The company has developed a suite of ultrasound-based devices to non-invasively measure the absolute value of intracranial pressure (ICP), real-time cerebral blood flow autoregulation (CA), and intracranial volumetric wave monitoring. The non-invasive diagnostic methods have been clinically tested and proven in leading neuro centers in Europe and the United States...
Read more
ViewRay designs, manufactures and markets MRIdian, the first and only MRI-guided radiation therapy system that images and treats cancer patients simultaneously...
Read more
PrIME Biologics
PrIME Biologics (PrIME) uses its revolutionary PrIME Technology to manufacture therapeutic plasma products that is currently underutilised by many emerging countries. The PrIME Technology in association with GE Healthcare based Chromatography in a process called PrIME + could potentially save many lives much of the world shortage of plasma products could be addressed could be saved. And address a market of about USD1bn...
Read more
Invendo Medical
Invendo Medical aims to become a globally leading developer and distributor of disposable, highly flexible and easy-to-use endoscopy products in the field of gastroenterology.

Invendo is focussed on an application in the diagnosis and treatment of colorectal cancers (CRC), the second leading cause of cancer death...
Read more
ConforMIS Inc.
ConforMIS, founded in 2004 and based in Bedford, Massachusetts, USA, creates personalised, patient-specific implants and disposable instrumentation utilising proprietary imaging technology. The company produces knee systems under the iUni, iDuo and iTotal brands. Each one has received FDA 510(k) clearance and carries the CE, supporting the multi-regional commercial approach...
Read more
Small Bone Innovations Inc.
The product portfolio of Small Bone Innovations Inc. (SBI), based in Morrisville, Pennsylvania, includes more than 40 devices designed specifically for small bone and joint surgery, such as thumb, wrist, finger, elbow, foot and ankle.

SBI's product suite has a "star" among its ranks—the Scandinavian Total Ankle Replacement System (the STAR Ankle)...
Read more
News & Events
Iconic Therapeutics appoints Julia P. Gregory to Board of Directors
April 6, 2017

According to William Greene, M.D., Chief Executive Officer, “Julia adds to the Board a uniquely rich background in the strategic financing, planning, partnering, and growth of both public and private biotech companies Read more
P2 Science Raises $9.55 Million in Series B Financing Round
March 1, 2017

P2 Science Inc., a venture-backed, biorenewable chemistry company, today announced the close of a $9.55 million Series B financing round. Read more
ViewRay Receives FDA 510(k) Clearance for MRIdian Linac Announces Fourth Quarter and Full Year 2016 Financial Highlights
February 27, 2017

ViewRay, Inc. (Nasdaq: VRAY) announced today that the company received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market the MRIdian Linac system, the company’s next generation linear accelerator-based MRI-guided radiation therapy system. “Our strong performance in 2016, combined with the $26.1 million we raised this January, positions us well for the launch and commercialization of MRIdian Linac,” said Ajay Bansal, chief financial officer of ViewRay. Read more
Iconic Therapeutics to Present Phase 2a Emerge Trial Results at Miami Meeting
February 9, 2017

Iconic Therapeutics, a clinical stage biopharmaceutical company dedicated to translating knowledge of Tissue Factor biology into new therapeutics for retinal disease and cancer, announced today that the results of its recently completed EMERGE trial. Read more
Chrono Therapeutics Raises $47.6 Million in Series B Financing to Advance its Clinical Platform for Personalized Drug Therapy
September 8, 2016

Chrono Therapeutics, a pioneer in digital drug therapy and recent recipient of the World Economic Forum Technology Pioneer Award, today announced that it has closed a $47.6 million Series B financing. Read more
invendo medical Announces FDA Clearance of the invendoscopy E200 System –Including the First and Only Sterile, Single-use Endoscope For Colonoscopies
September 7, 2016

invendo medical GmbH, a leading developer and distributor of sterile, single-use and robotically-assisted HD endoscopy products in the field of gastroenterology and GI surgery, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the invendoscopy E200 System, which includes the invendoscope SC200 - the first and only sterile, single-use colonoscope. Read more
Iconic Therapeutics Announces Final Close Of Series C Financing With Additional $10 Million Investment
August 9, 2016

Iconic Therapeutics, a clinical stage biopharmaceutical company dedicated to translating knowledge of Tissue Factor biology into new therapeutics for retinal disease and cancer, today announced the final closing of its Series C financing bringing an additional $10 million into the company and completing the Series C at $48.5 million. Read more
Acutus Medical Completes $75 Million Series C Financing
March 22, 2016

Financing will support quest to transform EP market by expanding clinical studies and upcoming European and U.S. launches of AcQMap. Read more
Dr Ivor Royston agrees to join ViroPro's Board of Directors
December 08, 2015

Viropro, which has signed a non-binding Letter of Intent for the acquisition of NovaRx, a San Diego based pioneer in immuno-oncology, has announced Dr. Ivor Royston has agreed to join its Board of Directors. Read more
Xeraya closes investment into Vittamed Corporation
October 16, 2015

Vittamed ("Company") has become Xeraya's second investment that is structured based on Shariah-compliant principles. The Mudharabah Innovation Fund (managed by Xeraya for the Ministry of Finance) will be a co-investor in Vittamed once the Company has achieved certain Malaysian-centricity milestones. Read more
ViewRay® Receives 2015 Frost & Sullivan Technology Innovation Leadership Award
October 13, 2015

ViewRay, a Xeraya portfolio company, has been awarded the 2015 Frost & Sullivan Technology Innovation Leadership Award, a prestigious recognition based on an extensive and independent Frost & Sullivan analysis of the North American Image-Guided Radiation Therapy market, for ViewRay's MRIdian® system on 13th October 2015. Read more
Sentinext recognized at BioMalaysia 2015
August 18, 2015
ViewRay completes Alternative Public Offering on US Exchange
July 23, 2015

ViewRay, Inc. (OTCQB: VRAY) announced its successful completion of a reverse merger with ViewRay Technologies, Inc. Read more

Go to News & Event